Premium
Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January...
November 9, 2022 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2022 Highlights Genmab revenue increased 60% compared to the first nine months of 2021, to DKK...
Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark; November 3, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance...
Company Announcement Net sales of DARZALEX® in the third quarter of 2022 totaled USD 2,052 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen...
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 5, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
August 10, 2022 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022 Highlights Genmab and AbbVie Inc. (AbbVie) announced topline results for epcoritamab from the Phase...
Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance...
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; August 2, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; July 20, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
Company Announcement Net sales of DARZALEX® in the second quarter of 2022 totaled USD 1,986 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
